Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy
Journal Title: The AAPS Journal - Year 2011, Vol 13, Issue 4
Abstract
The objective of this work was to examine the atazanavir–bilirubin relationship using a population-based approach and to assess the possible application of bilirubin as a readily available marker of atazanavir exposure. A model of atazanavir exposure and its concentration-dependent effect on bilirubin levels was developed based on 200 atazanavir and 361 bilirubin samples from 82 patients receiving atazanavir in the NORTHIV trial. The pharmacokinetics was adequately described by a one-compartment model with first-order absorption and lag-time. The maximum inhibition of bilirubin elimination rate constant (Imax) was estimated at 91% (95% CI, 87–94) and the atazanavir concentration resulting in half of Imax (IC50) was 0.30 μmol/L (95% CI, 0.24–0.37). At an atazanavir/ritonavir dose of 300/100 mg given once daily, the bilirubin half-life was on average increased from 1.6 to 8.1 h. A nomogram, which can be used to indicate suboptimal atazanavir exposure and non-adherence, was constructed based on model simulations.
Authors and Affiliations
Dinko Rekić, Oskar Clewe, Daniel Röshammar, Leo Flamholc, Anders Sönnerborg, Vidar Ormaasen, Magnus Gisslén, Angela Äbelö, Michael Ashton
Keywords
Related Articles
- EP ID EP681344
- DOI 10.1208/s12248-011-9299-0
- Views 46
- Downloads 0
Receptor-targeted gene delivery viafolate-conjugated polyethylenimine
A novel synthetic gene transfer vector was evaluated for tumor cell-specific targeted gene delivery. The folate receptor is a tumor marker overexpressed in more than 90% of ovarian carcinomas and large percentages of oth...
Comparison of Neutralizing Antibody Assays for Receptor Binding and Enzyme Activity of the Enzyme Replacement Therapeutic Naglazyme® (Galsulfase)
Most patients receiving Naglazyme® (galsulfase, rhASB) enzyme replacement therapy for mucopolysaccharidosis type VI develop an antibody response. To evaluate the impact of this response, two in vitro neutralizing...
Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples
Characterization of the stability of analytes in biological samples collected during clinical studies together with that of critical assay reagents, including analyte stock solutions, is recognized as an important compon...
Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis
Apoptosis is associated with cascades of biochemical changes, including caspase activation, cleavage of poly-ADP-ribose polymerase (PARP), and fragmentation of genomic DNA. Knowledge of the kinetics of these changes in d...
Statistical Power Calculations for Mixed Pharmacokinetic Study Designs Using a Population Approach
Simultaneous modelling of dense and sparse pharmacokinetic data is possible with a population approach. To determine the number of individuals required to detect the effect of a covariate, simulation-based power calculat...